Onyvax Company
Onyvax develops cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells.
Last Funding Type:
Series C
Funding Status:
Late Stage Venture
Headquarters:
Bradford, Somerset, United Kingdom
Founded Date:
1997-01-01
Last Funding Date:
2006-05-08
Total Funding:
29810445
Employee Number:
11-50
Investors Number:
5
Industry:
Whole-Cell Antigens